A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 459 participants.
Also called NCT01717300
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 459 participants
- Sponsor
- Registry
-
NCT01717300 -
2012-003110-14
-
- Other papers using this trial's data
- Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01717300. Randomized; double masking; primary purpose treatment. Start 2012-11-06 (actual); primary completion 2014-10-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Anacetrapib 100 mg
- Intervention (Drug)
- Placebo for anacetrapib 100 mg
- Intervention (Drug)
- Anacetrapib 25 mg
- Intervention (Drug)
- Placebo for anacetrapib 25 mg
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01717300- Content hash
732cf22d23e1d0992af65dbd5748486641ea9b43ce94a4eb2ebca2c73709036b